Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Adaptive Phage Therapeutics

Request full access

Provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria

Gaithersburg, United StatesFounded 2016Biotech & Life Sciences

About Adaptive Phage Therapeutics

Adaptive Phage Therapeutics (APT) is a clinical stage company focused on developing precision phage therapy to address the growing threat of multi-drug resistant (MDR) bacterial infections. Founded on pioneering research by NIH scientist Dr. Carl R. Merril and further explored by the US Navy's Biological Defense Research Directorate, APT aims to provide effective therapeutic responses where traditional antibiotics fail. The company operates in the biotechnology and healthcare market, primarily serving hospitals, healthcare providers, and patients affected by MDR infections. APT's business model revolves around the development and commercialization of phage-based treatments, including a phage susceptibility test in collaboration with the Mayo Clinic. Revenue is generated through clinical trials, partnerships, and eventual commercialization of their therapies.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2016
Headquarters
Gaithersburg, United States
Employees
10
Open positions
None listed
Dealroom signal
63.5/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Technology
Deep Tech
Business model
Manufacturing
Client focus
B2B

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Mar 2024 $0 — BiomX ↗
SERIES BOther financing Jun 2023 $12M $204M AMR Action Fund ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Adaptive Phage Therapeutics website traffic

Latest recorded traffic for Adaptive Phage Therapeutics is 130 monthly website visits, down 89.2% over the last three months. Adaptive Phage Therapeutics's team declined 60% over the past year.

Latest monthly visits130 3-month web change-89.2% 1-year team growth-60%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Adaptive Phage Therapeutics in the Gaithersburg ecosystem

Live from Dealroom

The Adaptive Phage Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • US Department of War
  • Military Health System

Series A5 investors entered at this stage

  • Alexandria Equities
  • Alexandria Venture Investments
  • Mayo Clinic
  • Deerfield
  • AMR Action Fund

Other known investors2 additional known investors

  • BiomX
  • National Institutes of Health
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Adaptive Phage Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Adaptive Phage Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.